| abstract |
Therapies without interferon and without ribavirin for the treatment of HCV. Preferably, the treatment is of a shorter duration, such as no more than 12 weeks. In one aspect, therapies comprise administering at least two direct-acting antiviral agents without interferon and without ribavirin to a subject with an HCV infection. For example, therapies comprise administering to a subject effective amounts of a therapeutic agent 1, a therapeutic agent 2 (or a therapeutic agent 3) and a cytochrome P450 inhibitor (eg, ritonavir). Claim 2: The method of claim 1, characterized in that said at least two DAAs comprise: a compound 1 or a pharmaceutically acceptable salt thereof, and a compound 4 or a pharmaceutically acceptable salt thereof, wherein compound 1 or the salt It is co-administered with ritonavir. Claim 10: The method of claim 1, characterized in that said at least two DAAs comprise PSI-7977 and TMC-435. Claim 14: The method of claim 1, characterized in that said at least two DAAs comprise PSI-7977 and daclatasvir. Claim 18: The method of claim 1, characterized in that said at least two DAAs comprise PSI-7977 and GS-5885. Claim 22: The method of claim 1, characterized in that said at least two DAAs comprise BMS-790052 and BMS-650032, and said treatment lasts for 10, 11 or 12 weeks. Claim 28: The method of claim 1, characterized in that said at least two DAAs comprise INX-189 and daclatasvir. |